Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As the Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia: A Single-Center Real World Study

Huayuan Zhu, Hui Shen, Yilian Yang, Chong-Yang Ding, MD, Yeqin Sha, Hongling Mi, Jingyan Qiu, Ruize Chen, Yujie Wu, Chun Qiao, Li Wang, MD, Lei Fan, MD PhD, Wei Xu, MD PhD, Jianyong Li, MD PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141747

Published: 2020

Journal Articles

Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies

Yuqin Song, MD PhD, Wei Xu, MD PhD, Yongping Song, MD, Lihong Liu, MD, Song Lin, Zhiming Li, MD PhD, Ting Liu, MD PhD, Shuhua Yi, MD, Daobin Zhou, MD PhD, Mingzhi Zhang, MD, Yu Hu, MD, Jie Jin, MD PhD, Huaqiang Zhu, MD, Zhengguang Lu, Renbin Zhao, PhD, Zhixin Xu, MD PhD, Jun Zhu, BS

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-140172

Published: 2020

Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Yan Gao, MD PhD, Huiqiang Huang, MDPhD, Xiaoxiao Wang, Bing Bai, Liling Zhang, MD PhD, Yin Xiao, Xinxiu Liu, Wenyu Li, PhD, Wei Xu, MD PhD, Ru Feng, Yu Chen, Huijing Wu, Jibin Li, Xue Wu

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-134665

Published: 2020

Journal Articles

Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141781

Published: 2020

Journal Articles

Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134531

Published: 2020

Journal Articles

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Blood (2019) 134 (Supplement_1): 4319.

https://doi.org/10.1182/blood-2019-123331

Published: 2019

Journal Articles

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Blood (2019) 134 (Supplement_1): 4450.

https://doi.org/10.1182/blood-2019-130121

Published: 2019

Journal Articles

SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL

Lei Fan, MD PhD, Chao Wang, Zhiqiang Wang, Xian Zhang, Lei Cao, Yi Miao, MD PhD, Xinyi Du, Wei Xu, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 5306.

https://doi.org/10.1182/blood-2019-129469

Published: 2019

Journal Articles

Association of Insurance Status and Marital Status with Outcomes of Patients with Chronic Lymphocytic Leukemia: A Population-Based Study

Yi Miao, MD PhD, Wei Xu, MD PhD, Lei Fan, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 5459.

https://doi.org/10.1182/blood-2019-127756

Published: 2019

Journal Articles

Mitochondrial Genome-Derived Mc-COX2 with Novel Characteristics Predicts Prognosis of Patients with Chronic Lymphocytic Leukemia

Hui Jin, Jianyong Li, MD, Zijuan Wu, Handong Sun, Yi Xia, Jianxin Fu, MD PhD, Lei Fan, MD PhD, Wei Xu, MD PhD, Li Wang, MD

Blood (2019) 134 (Supplement_1): 4284.

https://doi.org/10.1182/blood-2019-124609

Published: 2019

Journal Articles

PTBP1 Regulates Alternative Splicing of Apoptotic Protein: Implications in CLL and Ibrutinib Resistance

Huayuan Zhu, Xiaotong Li, Xinqi Zheng, Juejin Wang, Hanning Tang, Wei Xu, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 1290.

https://doi.org/10.1182/blood-2019-126945

Published: 2019

Journal Articles

Circ-RPL15: A Plasma Circular RNA As Novel Oncogenic Driver to Promote Progression of Chronic Lymphocytic Leukemia

Hui Jin, Handong Sun, Zijuan Wu, Yi Xia, Jianxin Fu, MD PhD, Wei Xu, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 3020.

https://doi.org/10.1182/blood-2019-126610

Published: 2019

Journal Articles

Laterality and Survival Outcomes in Patients with Primary Testicular Diffuse Large B Cell Lymphoma

Yi Miao, MD PhD, Lei Fan, MD PhD, Wei Xu, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 2903.

https://doi.org/10.1182/blood-2019-129952

Published: 2019

Journal Articles

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients in China in the Rituximab Era

Yun Li, MD PhD, Meng Wu, MD, Huiqiang Huang, MD PhD, Wei Xu, MD PhD, Haiwen Huang, MD PhD, Weili Zhao, MD PhD, Yanyan Wang, MD, Shuo Liu, MD, Pengpeng Xu, MD, Zhengming Chen, Yuqin Song, MD PhD, Jia Ruan, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 3994.

https://doi.org/10.1182/blood-2019-125192

Published: 2019

Journal Articles

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Wei Xu, MD PhD, Jie Jin, MD PhD, Keshu Zhou, MD, Li Wang, MD, Huayuan Zhu, Jiejing Qian, Jianying Huang, Fuling Zhou, MD, Xiaohong Xu, Zhiqiang Wang, Wei Guo, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 4000.

https://doi.org/10.1182/blood-2019-126707

Published: 2019

Journal Articles

Genomic Landscape of Chinese Patients with Chronic Lymphocytic Leukemia By Whole-Exome Sequencing

Yi Miao, MD PhD, Yi Xia, Chun Qiao, Huayuan Zhu, Jiazhu Wu, MD, Hui Jin, Jianxin Fu, MD PhD, Li Wang, MD, Lei Fan, MD PhD, Wei Xu, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 2784.

https://doi.org/10.1182/blood-2019-127813

Published: 2019

Journal Articles

Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Blood (2019) 134 (Supplement_1): 755.

https://doi.org/10.1182/blood-2019-126305

Published: 2019

Journal Articles

Functional Evaluation and Mechanism Study of Kel As an Oncogenic Driver in Acute Erythroleukemia

Hui Jin, Jianyong Li, MD, Zijuan Wu, Handong Sun, Wenjie Liu, MD, Yanfeng Liu, PhD, Ming Hong, MD PhD, Sixuan Qian, Wei Xu, MD PhD

Blood (2019) 134 (Supplement_1): 1246.

https://doi.org/10.1182/blood-2019-124607

Published: 2019

Journal Articles

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

Blood (2018) 132 (Supplement 1): 148.

https://doi.org/10.1182/blood-2018-99-117956

Published: 2018

Journal Articles

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Junyuan Qi, PhD, Yuqin Song, MD PhD, Bo Jiang, PhD, Jianyong Li, PhD, Meifeng Tu, PhD, Lingyan Ping, MD PhD, Zengjun Li, PhD, Wei Xu, MD PhD, Huayuan Zhu, MD PhD, Jun Zhu, MD PhD, Hanying Bao, MD PhD, Zusheng Xu, PhD, Lugui Qiu, MD PhD

Blood (2018) 132 (Supplement 1): 5332.

https://doi.org/10.1182/blood-2018-99-110585

Published: 2018

NARROW

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As the Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia: A Single-Center Real World Study

Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL

Association of Insurance Status and Marital Status with Outcomes of Patients with Chronic Lymphocytic Leukemia: A Population-Based Study

Mitochondrial Genome-Derived Mc-COX2 with Novel Characteristics Predicts Prognosis of Patients with Chronic Lymphocytic Leukemia

PTBP1 Regulates Alternative Splicing of Apoptotic Protein: Implications in CLL and Ibrutinib Resistance

Circ-RPL15: A Plasma Circular RNA As Novel Oncogenic Driver to Promote Progression of Chronic Lymphocytic Leukemia

Laterality and Survival Outcomes in Patients with Primary Testicular Diffuse Large B Cell Lymphoma

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients in China in the Rituximab Era

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Genomic Landscape of Chinese Patients with Chronic Lymphocytic Leukemia By Whole-Exome Sequencing

Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Functional Evaluation and Mechanism Study of Kel As an Oncogenic Driver in Acute Erythroleukemia

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only